Results 71 to 80 of about 753,406 (101)
Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease. [PDF]
An H +26 more
europepmc +1 more source
3D Differentiation of Bone-Marrow Derived Mesenchymal Stromal Cells into the Keratocyte Lineage for Corneal Bioprinting. [PDF]
Taoum A +8 more
europepmc +1 more source
Effects of Phenoxazine Chromophore on Optical, Electrochemical and Electrochromic Behaviors of Carbazole-Thiophene Derivatives. [PDF]
Hu B +5 more
europepmc +1 more source
TRPA1-Activated Peptides from Saiga Antelope Horn: Screening, Interaction Mechanism, and Bioactivity. [PDF]
Wang C, Wu C, Song L.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Managing treatment fluctuations in Parkinson disease
Neurology, 2019The first truly effective medical therapy for Parkinson disease (PD), levodopa, was introduced in the 1960s. Patients had to take huge doses of levodopa, with treatment limited by peripheral decarboxylation of levodopa to dopamine by dopa decarboxylase ...
W. Metzer, F. B. Rodrigues
semanticscholar +1 more source
European journal of drug metabolism and pharmacokinetics, 1976
J. Jonsson, T. Lewander
semanticscholar +1 more source
J. Jonsson, T. Lewander
semanticscholar +1 more source

